Klebsiella pneumoniae Infections - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H2 2016, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 22 and 14 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively for Klebsiella pneumoniae Infections.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Klebsiella pneumoniae Infections Overview 7
Therapeutics Development 8
Pipeline Products for Klebsiella pneumoniae Infections - Overview 8
Pipeline Products for Klebsiella pneumoniae Infections - Comparative Analysis 9
Klebsiella pneumoniae Infections - Therapeutics under Development by Companies 10
Klebsiella pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes 12
Klebsiella pneumoniae Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Klebsiella pneumoniae Infections - Products under Development by Companies 16
Klebsiella pneumoniae Infections - Products under Investigation by Universities/Institutes 18
Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development 19
Appili Therapeutics Inc 19
Arsanis, Inc. 20
Cellceutix Corporation 21
Debiopharm International SA 22
Evaxion Biotech ApS 23
F. Hoffmann-La Roche Ltd. 24
FOB Synthesis, Inc. 25
Melinta Therapeutics, Inc 26
Merck & Co., Inc. 27
MicuRx Pharmaceuticals, Inc. 28
Nosopharm SAS 29
Peptilogics, Inc. 30
Pfizer Inc. 31
Phico Therapeutics Limited 32
Procarta Biosystems Limited 33
Sarepta Therapeutics, Inc. 34
Shionogi & Co., Ltd. 35
Soligenix, Inc. 36
Sumitomo Dainippon Pharma Co., Ltd. 37
Syntiron LLC 38
Tetraphase Pharmaceuticals Inc. 39
Varinel, Inc. 40
Klebsiella pneumoniae Infections - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile 50
ASN-300 - Drug Profile 51
ATI-1503 - Drug Profile 52
CA-824 - Drug Profile 53
CB-027 - Drug Profile 54
CB-618 - Drug Profile 55
CC-1807 - Drug Profile 56
CTIX-1278 - Drug Profile 57
Debio-1454 - Drug Profile 58
dusquetide - Drug Profile 59
FSI-1671 - Drug Profile 63
FSI-1686 - Drug Profile 64
GNEG SNARE - Drug Profile 65
IBN-1 - Drug Profile 66
klebsiella pneumonia vaccine - Drug Profile 67
Klebsiella pneumoniae vaccine - Drug Profile 68
Klebsiella pneumoniae vaccine - Drug Profile 69
Klebsiella pneumoniae vaccine - Drug Profile 70
mirandamycin - Drug Profile 71
MRX-V - Drug Profile 72
NOSO-95179 - Drug Profile 73
Onc-72 - Drug Profile 74
Peptides for Infectious Diseases - Drug Profile 75
PMX-100 - Drug Profile 76
PMX-1091 - Drug Profile 77
PMX-1142 - Drug Profile 78
PMX-229 - Drug Profile 79
PMX-633 - Drug Profile 80
PT-4 - Drug Profile 81
RX-05 - Drug Profile 82
RXP-873 - Drug Profile 83
S-649266 - Drug Profile 84
SM-295291 - Drug Profile 86
SM-369926 - Drug Profile 87
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 88
Small Molecules for Bacterial Infections - Drug Profile 89
Small Molecules for Bacterial Infections - Drug Profile 90
Small Molecules for Klebsiella pneumoniae Infections - Drug Profile 91
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 92
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 93
SPR-741 - Drug Profile 95
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 96
TP-6076 - Drug Profile 97
VAR-10100 - Drug Profile 98
Klebsiella pneumoniae Infections - Dormant Projects 99
Klebsiella pneumoniae Infections - Discontinued Products 101
Klebsiella pneumoniae Infections - Product Development Milestones 102
Featured News & Press Releases 102
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 104
Disclaimer 105

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H2 2016 11
Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, H2 2016 22
Klebsiella pneumoniae Infections - Pipeline by Arsanis, Inc., H2 2016 23
Klebsiella pneumoniae Infections - Pipeline by Cellceutix Corporation, H2 2016 24
Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA , H2 2016 25
Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS, H2 2016 26
Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 27
Klebsiella pneumoniae Infections - Pipeline by FOB Synthesis, Inc., H2 2016 28
Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H2 2016 29
Klebsiella pneumoniae Infections - Pipeline by Merck & Co., Inc., H2 2016 30
Klebsiella pneumoniae Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016 31
Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H2 2016 32
Klebsiella pneumoniae Infections - Pipeline by Peptilogics, Inc., H2 2016 33
Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc., H2 2016 34
Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Limited, H2 2016 35
Klebsiella pneumoniae Infections - Pipeline by Procarta Biosystems Limited, H2 2016 36
Klebsiella pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016 37
Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H2 2016 38
Klebsiella pneumoniae Infections - Pipeline by Soligenix, Inc., H2 2016 39
Klebsiella pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 40
Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H2 2016 41
Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 42
Klebsiella pneumoniae Infections - Pipeline by Varinel, Inc., H2 2016 43
Assessment by Monotherapy Products, H2 2016 44
Number of Products by Stage and Target, H2 2016 46
Number of Products by Stage and Mechanism of Action, H2 2016 48
Number of Products by Stage and Route of Administration, H2 2016 50
Number of Products by Stage and Molecule Type, H2 2016 52
Klebsiella pneumoniae Infections - Dormant Projects, H2 2016 102
Klebsiella pneumoniae Infections - Dormant Projects (Contd..1), H2 2016 103
Klebsiella pneumoniae Infections - Discontinued Products, H2 2016 104